THE STATUS OF HPV TESTING IN THE DIAGNOSIS OF CERVICAL CANCER AND HEAD AND NECK TUMORS: EXCHANGE OF FOREIGN EXPERIENCE

G. A. Milovanova – Resident, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
K. T. Kasoyan – MD, PhD, Associate Professor at the Department of Clinical Laboratory Diagnostics of the Russian Medical Academy of Postgrduate Professional Education of the Ministry of Health of the Russian Federation, Doctor of Clinical Laboratory Diagnostics Cytologis. Member of the International Academy of Cytology (MIAC), Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..
O. I. Patsap – MD, PhD, Federal Center of Brain Research and Neurotechnologies FMBA, Moscow, Russia. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..

1. Chan CK, Aimagambetova G, Ukybassova T, et al. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination. Review of cur-rent perspectives. J Oncol. 2019;2019:3257939. Published 2019 Oct 10. doi: 10.1155/2019/3257939
2. Renshaw AA, Young NA, Birdsong GG, et al. Comparison of performance of conventional and ThinPrep gynecologic preparations in the College of american pathologists gynecologic cytology program. Arch Pathol Lab Med. 2004;128(1):17-22. doi: 10.5858/2004-128-17-COPOCA
3. Abulafia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol. 2003;90(1):137-44. doi: 10.1016/s0090-8258(03)00176-8
4. Vassilakos P, Schwartz D, de Marval F, et al. Biopsy-based comparison of liquid-based, thin-layer prepa-rations to conventional Pap smears. J Reprod Med. 2000; 45(1):11-6.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. doi: 10.1002/ (SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
6. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persis-tent cervical dysplasia. J Natl Cancer Inst. 1995;87(18): 1365-71. doi: 10.1093/jnci/87.18.1365
7. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer [published correction appears in Vaccine. 2013 Dec 16;31(52):6266]. Vaccine. 2012; 30 Suppl 5:F88-F99. doi: 10.1016/j.vaccine.2012.06.095
8. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810-9. doi: 10.7326/0003-4819-132-10-200005160-00009
9. Ronco G, Dillner J, Elfstr?m KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials [published correction appears in Lancet. 2015 Oct 10;386(10002):1446]. Lancet. 2014;383(9916):524-32. doi: 10.1016/S0140-6736(13)62218-7
10. Isidean SD, Mayrand MH, Ramanakumar AV, et al. Human papillomavirus testing versus cytology in pri-mary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer. 2016;139(11):2456-66. doi: 10.1002/ijc.30385
11. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. Published 2008 Oct 13. doi: 10.1136/bmj.a1754
12. Gage JC, Schiffman M, Katki HA, et al. Reassur-ance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8):dju153. Published 2014 Jul 18. doi: 10.1093/jnci/dju153
13. Olivas AD, Barroeta JE, Lastra RR. Role of ancil-lary techniques in gynecologic cytopathology specimens. Acta Cytol. 2020;64(1-2):63-70. doi: 10.1159/000496569
14. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice [published correction appears in Lancet Oncol. 2011 Aug;12(8):722]. Lancet Oncol. 2011;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0
15. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8
16. Rebolj M, Lynge E, Bonde J. Human papilloma-virus testing and genotyping in cervical screening. Expert rev anticancer ther. 2011;11(7):1023-31. doi: 10.1586/era.11.84
17. Mu?oz N, Bosch FX, de Sanjos? S, et al. Epidemi-ologic classification of human papillomavirus types associ-ated with cervical cancer. N Engl J Med. 2003;348(6):518-27. doi: 10.1056/NEJMoa021641
18. Pirog EC, Lloveras B, Molijn A, et al. HPV preva-lence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014;27(12):1559-67. doi: 10.1038/modpathol.2014.55
19. Saslow D, Solomon D, Lawson HW, et al. Ameri-can cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3): 147-72.
20. Castle PE, Stoler MH, Wright TC Jr, et al. Perfor-mance of carcinogenic human papillomavirus (HPV) test-ing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880-90.
21. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136(2):189-97. doi: 10.1016/j.ygyno.2014.11.076
22. Huh WK, Williams E, Huang J, et al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy. 2015;13(1):95-107. doi: 10.1007/s40258-014-0135-4
23. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) Immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35(3):210-20. doi: 10.1016/j.ctrv.2008.10.005
24. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9(10):937-45. doi: 10.1016/S1470-2045(08)70208-0
25. Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 Dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst. 2015;107(12):djv257. Published 2015 Sep 15. doi: 10.1093/jnci/djv257
26. Luttmer R, Dijkstra MG, Snijders PJ, et al. p16/Ki-67 Dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol. 2016;29(8):870-8. doi: 10.1038/ modpathol.2016.80
27. Wright TC Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144(1):51-6. doi: 10.1016/j.ygyno.2016.10.031
28. Bergeron C, Ikenberg H, Sideri M, et al. Prospec-tive evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015;123(6): 373-81. doi: 10.1002/cncy.21542
29. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001; 234(1):10-20. doi: 10.1097/00000658-200107000-00003
30. Rodr?guez-Paredes M, Esteller M. Cancer epige-netics reaches mainstream oncology. Nat Med. 2011;17(3): 330-9. doi: 10.1038/nm.2305
31. Galv?n SC, Mart?nez-Salazar M, Galv?n VM, et al. Analysis of CpG methylation sites and CGI among human papillomavirus DNA genomes. BMC Genomics. 2011;12:580. Published 2011 Nov 25. doi: 10.1186/1471-2164-12-580
32. Kalantari M, Calleja-Macias IE, Tewari D, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol. 2004;78(23):12762-72. doi: 10.1128/JVI.78.23.12762-12772.2004
33. Mirabello L, Schiffman M, Ghosh A, et al. Elevat-ed methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer. 2013;132(6):1412-22. doi: 10.1002/ijc.27750
34. Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3(1):78-81. doi: 10.1007/s12105-009-0100-y
35. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. doi: 10.1200/JCO.2011.36.4596
36. Chernock RD, El-Mofty SK, Thorstad WL, et al. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol. 2009; 3(3):186-94. doi: 10.1007/s12105-009-0126-1
37. Lewis JS Jr, Khan RA, Masand RP, et al. Recogni-tion of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma – a prospective cohort and interobserver variability study. Histopathology. 2012;60(3): 427-36. doi: 10.1111/j.1365-2559.2011.04092.x
38. Gondim DD, Haynes W, Wang X, et al. Histologic typing in oropharyngeal squamous cell carcinoma: a 4-year prospective practice study with p16 and high-risk HPV mRNA testing correlation. Am J Surg Pathol. 2016;40(8):1117-24. doi: 10.1097/PAS.0000000000000650
39. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012;6 Suppl 1(Suppl 1):S75-S82. doi: 10.1007/s12105-012-0369-0
40. Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of american pathologists. Arch Pathol Lab Med. 2018;142(5):559-97. doi: 10.5858/arpa.2017-0286-CP
41. Huang CC, Qiu JT, Kashima ML, et al. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol. 1998;11(10):971-7.
42. Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35(9): 1343-50. doi: 10.1097/PAS.0b013e318220e59d
43. Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012;36(12):1874-82. doi: 10.1097/PAS.0b013e318265fb2b
44. Begum S, Gillison ML, Nicol TL, Westra WH. Detection of human papillomavirus-16 in fine-needle aspi-rates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(4):1186-91. doi: 10.1158/1078-0432.CCR-06-1690
45. Holmes BJ, Maleki Z, Westra WH. The fidelity of p16 staining as a surrogate marker of human papilloma-virus status in fine-needle aspirates and core biopsies of neck node metastases: implications for HPV testing pro-tocols. Acta Cytol. 2015;59(1):97-103. doi: 10.1159/000375148
46. Jalaly JB, Lewis JS Jr, Collins BT, et al. Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx. Cancer Cytopathol. 2015;123(12):723-31. doi: 10.1002/cncy.21600
47. Xu B, Ghossein R, Lane J, Lin O, Katabi N. The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma. Hum Pathol. 2016;54:193-200. doi: 10.1016/j.humpath.2016.04.002
48. Allison DB, Miller JA, Coquia SF, Maleki Z. Ultrasonography-guided fine-needle aspiration with concur-rent small core biopsy of neck masses and lymph nodes yields adequate material for HPV testing in head and neck squamous cell carcinomas. J Am Soc Cytopathol. 2016; 5(1):22-30.
49. Jannapureddy S, Cohen C, Lau S, et al. Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases. Diagn Cytopathol. 2010;38(11): 795-800. doi: 10.1002/dc.21293
50. Hou Y, Chaudhary S, Shen R, Li Z. Fine-needle aspiration of cervical lymph nodes yields adequate materi-als for accurate HPV testing in metastatic head and neck squamous cell carcinomas. Diagn Cytopathol. 2016;44(10): 792-8. doi: 10.1002/dc.23548
51. de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76 (Pt 4):1057-62. doi: 10.1099/0022-1317-76-4-1057
52. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35(3):791-5. doi: 10.1128/jcm.35.3.791-5.1997
53. Channir HI, Gr?nh?j Larsen C, Ahlborn LB, et al. Validation study of HPV DNA detection from stained FNA smears by polymerase chain reaction: improving the diagnostic workup of patients with a tumor on the neck. Cancer Cytopathol. 2016;124(11):820-7. doi: 10.1002/cncy.21753
54. Sivars L, Landin D, Haeggblom L, et al. Human papillomavirus DNA detection in fine-needle aspirates as indicator of human papillomavirus-positive oropharyn-geal squamous cell carcinoma: a prospective study. Head Neck. 2017;39(3):419-26. doi: 10.1002/hed.24641
55. Poljak M, Brencic A, Seme K, et al. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol. 1999;37(3):796-7. doi: 10.1128/JCM.37.3.796-797.1999
56. Schiffman M, Wheeler CM, Dasgupta A, et al.; ALTS Group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol. 2005; 124(5):722-32. doi: 10.1309/E067-X0L1-U3CY-37NW
57. Bishop JA, Maleki Z, Valsamakis A, et al. Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol. 2012;120(1):18-25. doi: 10.1002/cncy.20175
58. Smith DF, Maleki Z, Coughlan D, et al. Human papillomavirus status of head and neck cancer as deter-mined in cytologic specimens using the hybrid-capture 2 assay. Oral Oncol. 2014;50(6):600-4. doi: 10.1016/j.oraloncology.2014.02.011
59. Rao A, Young S, Erlich H, et al. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013;51(5):1478-84. doi: 10.1128/ JCM.03386-12
60. Kerr DA, Pitman MB, Sweeney B, et al. Perfor-mance of the Roche cobas 4800 high-risk human papillo-mavirus test in cytologic preparations of squamous cell carcinoma of the head and neck. Cancer Cytopathol. 2014; 122(3):167-74. doi: 10.1002/cncy.21372
61. Baldassarri R, Aronberg R, Levi AW, et al. Detection and genotype of high-risk human papillomavirus in fine-needle aspirates of patients with metastatic squa-mous cell carcinoma is helpful in determining tumor origin. Am J Clin Pathol. 2015;143(5):694-700.
62. Chernesky M, Jang D, Schweizer J, et al. HPV E6 oncoproteins and nucleic acids in neck lymph node fine needle aspirates and oral samples from patients with oropharyngeal squamous cell carcinoma. Papillomavirus Res. 2018;6:1-5. doi: 10.1016/j.pvr.2018.05.003
63. Day SP, Hudson A, Mast A, et al. Analytical per-formance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol. 2009;45 Suppl 1:S63-S72. doi: 10.1016/S1386-6532(09)70010-1
64. Einstein MH, Martens MG, Garcia FA, et al. Clinical validation of the Cervista HPV HR and 16/18 gen-otyping tests for use in women with ASC-US cytology. Gynecol Oncol. 2010;118(2):116-22. doi: 10.1016/j.ygyno.2010.04.013
65. Solomides CC, Bibbo M, Wang ZX. Assessment of fine needle aspiration specimen adequacy for high-risk HPV detection and genotyping in oropharyngeal squamous cell carcinoma. Acta Cytol. 2012;56(2):196-8. doi: 10.1159/000335730
66. Guo M, Khanna A, Dhillon J, et al. Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol. 2014;122(2): 96-103. doi: 10.1002/cncy.21375
67. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA HPV Assay. J Clin Virol. 2009;45 Suppl 1:S39-S47. doi: 10.1016/S1386-6532(09)70007-1
68. Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45 Suppl 1:S55-S61. doi: 10.1016/S1386-6532(09)70009-5
69. Han M, Bernadt CT, Murray B, et al. Aptima HR-HPV testing from diff-quick-stained fine-needle aspira-tion smears of oropharyngeal squamous cell carcinoma. J Am Soc Cytopathol. 2016;5(4):221-6. doi: 10.1016/j.jasc.2016.05.001
70. Schweizer J, Lu PS, Mahoney CW, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010;48(12):4646-8. doi: 10.1128/JCM.01315-10
71. Yu L, Jiang M, Qu P, et al. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage. Int J Cancer. 2018;143(4):813-22. doi: 10.1002/ijc.31368
72. van Hamont D, van Ham MA, Bakkers JM, et al. Evaluation of the SPF10-INNO LiPA human papilloma-virus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol. 2006;44(9):3122-9. doi: 10.1128/JCM.00517-06
73. Takes RP, Kaanders JH, van Herpen CM, et al. Human papillomavirus detection in fine needle aspiration cytology of lymph node metastasis of head and neck squa-mous cell cancer. J Clin Virol. 2016;85:22-6. doi: 10.1016/j.jcv.2016.10.008
74. Rollo F, Don? MG, Pellini R, et al. Cytology and direct human papillomavirus testing on fine needle aspirates from cervical lymph node metastases of patients with oropharyngeal squamous cell carcinoma or occult primary. Cytopathology. 2018;29(5):449-54. doi: 10.1111/cyt.12581
75. Don? MG, Giuliani M, Vocaturo A, et al. Cytology and human papillomavirus testing on cytobrushing samples from patients with head and neck squamous cell carcinoma. Cancer. 2014;120(22):3477-84. doi: 10.1002/cncr.28909